Search results: Found 2

Listing 1 - 2 of 2
Sort by
Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889452637 Year: Pages: 84 DOI: 10.3389/978-2-88945-263-7 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General)
Added to DOAB on : 2018-02-27 16:16:44
License:

Loading...
Export citation

Choose an application

Abstract

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.

Molecular Research of Endometrial Pathophysiology

Authors: ---
ISBN: 9783039214952 / 9783039214969 Year: Pages: 378 DOI: 10.3390/books978-3-03921-496-9 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Social Sciences --- Sociology
Added to DOAB on : 2019-12-09 16:10:12
License:

Loading...
Export citation

Choose an application

Abstract

The endometrium has been the subject of intense research in a variety of clinical settings, because of its importance in the reproductive process and its role in women’s health. In the past 15 years, significant efforts have been invested in defining the molecular phenotype of the receptive phase endometrium as well as of various endometrial pathologies. Although this has generated a wealth of information on the molecular landscape of human endometrium, there is a need to complement this information in light of the novel methodologies and innovative technical approaches. The focus of this International Journal of Molecular Sciences Special Issue is on molecular and cellular mechanisms of endometrium and endometrium-related disorders. The progress made in the molecular actions of steroids, in the metabolism of steroids and intracrinology, in endometrial intracellular pathways, in stem cells biology, as well as in the molecular alterations underlying endometrium-related pathologies has been the focus of the reviews and papers included.

Keywords

RANK --- endometrium --- endometrial cancer --- prognosis --- immunohistochemistry --- gene expression --- endometriosis --- developmental pathway --- pathogenomics --- mesenchymal stem cells --- endometrial cancer --- mtDNA mutations --- deficit of complex I --- antioxidant response --- mitochondrial biogenesis --- mitochondrial dynamics --- mitophagy --- miRNA --- lncRNAs --- endometrial cancer --- endometriosis --- chronic endometritis --- cell contacts --- tight junction --- adherens junction --- gap junction --- endometrium --- implantation --- decidualization --- endometriosis --- endometrial cancer --- liquid biopsy --- uterine aspirate --- circulating tumour cells (CTCs) --- circulating tumour DNA (ctDNA) --- exosomes --- Vitamin D --- endometrium --- endometrial cancer --- endometrial cancer --- preclinical models --- translational research --- endometrial cancer --- type II endometrial carcinoma --- targeted therapy --- kinase inhibitor --- molecular marker --- protein kinase --- protein phosphatase --- PP2A --- PPP2R1A --- SMAP --- endometriosis --- infertility --- niche --- inflammation --- immunomodulation --- mesenchymal stem cell --- orthoxenograft --- uterine cancer --- avatar --- murine models --- personalized medicine --- targeted therapy --- preclinical studies --- translational research --- endometriosis --- TRP channels --- endometrial stromal cells --- eutopic and ectopic endometrium --- endometrial cell --- pathway --- proliferation --- decidualization --- migration --- angiogenesis --- regeneration --- breakdown --- implantation --- endometrial cancer --- orthotopic xenograft model --- estrogen dependent --- bioluminescence imaging --- contrast-enhanced CT scan --- endometrium --- adult stem cells --- endometrial regeneration --- stem cell markers --- endometriosis --- endometrial cancer --- decidualisation --- oestradiol --- aromatase --- testosterone --- dehydroepiandrosterone (DHEA) --- endometriosis --- endometrial cancer --- sulfatase --- endometriosis --- ectopic stroma --- microRNA --- small RNA sequencing --- EDN1 --- HOXA10 --- miR-139-5p --- miR-375 --- CTCF --- tumour suppressor gene --- haploinsufficiency --- zinc finger --- CRISPR/Cas9 --- cancer --- endometrial cancer --- gene editing --- phosphoinositide 3-kinase --- PIK3CA --- PIK3CB --- p110? --- p110? --- endometrial cancer --- LGR5 --- endometrium --- endometriosis --- menstrual cycle --- macrophages

Listing 1 - 2 of 2
Sort by
Narrow your search